Juan Carlos Jaramillo
Hoofd Techniek/Wetenschap/O&O bij VALNEVA
Vermogen: 199 834 $ op 31-05-2024
Oorsprong van het eerstegraads netwerk van Juan Carlos Jaramillo
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
20
| Public Company | Biotechnology | 20 |
Grünenthal GmbH
 Grünenthal GmbH Pharmaceuticals: MajorHealth Technology Grünenthal GmbH engages in the research and development of pharmaceutical products. It specializes in pain, gout, and inflammation. The company was founded by Hermann Wirtz in 1946 and is headquartered in Aachen, Germany.
1
| Subsidiary | Pharmaceuticals: Major | 1 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Juan Carlos Jaramillo via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| SEQUANS COMMUNICATIONS S.A. | Semiconductors | Director/Board Member | |
| Stanford University | College/University | Graduate Degree Masters Business Admin | |
Groupe Limagrain Holding SA
 Groupe Limagrain Holding SA Agricultural Commodities/MillingProcess Industries Groupe Limagrain Holding SA engages in agricultural production. It offers wheat, corn, maize, sunflower, rapeseed, tomato, carrot, melon, cauliflower, and pepper, as well as flower seeds. The company was founded in 1965 and is headquartered in Saint-Beauzire, France. | Agricultural Commodities/Milling | Director/Board Member | |
| University of Oxford | College/University | Undergraduate Degree | |
Xention Pharma Ltd.
 Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Pharmaceuticals: Major | Director/Board Member | |
| IOMAI CORPORATION | Biotechnology | Director/Board Member Chief Executive Officer | |
Groupe Grimaud La Corbière SA
 Groupe Grimaud La Corbière SA BiotechnologyHealth Technology Groupe Grimaud La Corbière SA specializes in biopharmaceutical and animal genetic solutions. It operates under two segments: Genetic Selection and sale of animal breeders such as broiler, and layer chickens, pigs, ducks, guinea, fowl, rabbits and pigeons; while Biopharmacy serves human and animal health such as vaccines, pharmaceutical proteins and serums for specific pathogen. The company was founded in 1966 and is headquartered in Roussay, France. | Biotechnology | Chief Executive Officer Director/Board Member | |
| INNATE PHARMA | Pharmaceuticals: Major | Director/Board Member | |
Euronext Paris SA
 Euronext Paris SA Investment Banks/BrokersFinance Euronext Paris SA operates as a stock exchange which provides solutions for regulated stock and derivatives markets in France. Its services include facilitating public offerings, providing trading facilities for cash and derivatives products, and supplying market data. The company was founded on January 20, 1988 and is headquartered in Courbevoie, France. | Investment Banks/Brokers | Director/Board Member | |
| DBV TECHNOLOGIES | Pharmaceuticals: Major | Director/Board Member | |
| ABIONYX PHARMA | Pharmaceuticals: Major | Director/Board Member | |
| Institut d'Études Politiques d'Aix-en-Provence | College/University | Undergraduate Degree | |
BPIFrance Investissement SAS
 BPIFrance Investissement SAS Investment ManagersFinance BPIFrance Investissement SAS (BPIfrance Investissement) is the private equity arm and subsidiary of State-owned Banque Publique d'Investissement in France. Formerly known as CDC Entreprises SAS, the firm was established in 1994 to carry out public-interest missions such as employment creation and momentum initiation in the private equity field. In 2013 they became BPIfrance Investissement when CDC Entreprises, FSI and FSI Régions merged. Headquartered in Paris, BPIfrance Investissement invests of behalf of the Government of France, as well as for third parties including FEI-Fonds Européen d'Investissement, BEI-Banque Européenne d'Investissement and BPCE SA. The firm invests directly or indirectly in SMEs and intermediate-sized companies at all stages of their development. | Investment Managers | Private Equity Analyst | |
Novasep Holding SAS
 Novasep Holding SAS Chemicals: Major DiversifiedProcess Industries Novasep Holding SAS provides manufacturing solutions for the life science industries. Its products include agrochemicals fine chemicals and food ingredients. The company was founded by Roger-Marc Nicoud in 1995 and is headquartered in Lyon, France. | Chemicals: Major Diversified | Director/Board Member | |
Heptares Therapeutics Ltd.
 Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
eZono AG
 eZono AG Medical SpecialtiesHealth Technology eZono AG develops portable ultrasound system. Its product eZono 3000 is a portable ultrasound system designed for the needs of anaesthetists. The company was founded by Allan R. Dunbar and Andre Jaekel in July 2004 and is headquartered in Jena, Germany. | Medical Specialties | Director/Board Member | |
| MVM Executive Ltd. | Director/Board Member | ||
| MVM (CIP) (No.3) Ltd. | Director/Board Member | ||
| MVM (CIP) (No.2) Ltd. | Director/Board Member | ||
| MVM (GP) Ltd. | Director/Board Member | ||
| MVM (GP) (No. 2) Ltd. | Director/Board Member | ||
Fonds Stratégique d'Investissement Fund
 Fonds Stratégique d'Investissement Fund Investment ManagersFinance Fonds Stratégique d'Investissement was created by the French Government in 2008 and integrated BPIFrance on 2013. This fund invests in small and middle sized French companies. | Investment Managers | Chief Investment Officer | |
Dassiet Oy
 Dassiet Oy Medical SpecialtiesHealth Technology Onbone Oy develops medical casting and splinting materials for use in the fields of orthopaedics, traumatology and occupational therapy. The company was founded by Petro Antero Kirmo Lahtinen, Antti Pärssinen, Jari Juhani Salo, Matti Eino Olavi Vaheri, and Karri Airola on November 18, 2008 and is headquartered in Oulu, Finland. | Medical Specialties | Director/Board Member | |
Bpifrance Participations SA /PRIVATE EQUITY/
 Bpifrance Participations SA /PRIVATE EQUITY/ Investment ManagersFinance Bpifrance Participations SA/ PRIVATE EQUITY/ (BPIfrance Participations PE) is the private equity division of Bpifrance Participations SA subsidiary of State-owned Caisse des Dépots & Consignations headquartered in France. Formerly known as Fonds Stratégique d'Investissement SA (Private Equity), the firm was established in 2008 by the Government of France in an aim to strengthen distressed companies of strategic importance for the French economy. Based in Paris, BPIfrance Participations specializes in fund of funds and direct investments in French intermediate-sized companies. | Investment Managers | Private Equity Investor | |
Valneva Scotland Ltd.
 Valneva Scotland Ltd. BiotechnologyHealth Technology Part of Valneva SE, Valneva Scotland Ltd. is a British vaccine company that specializes in the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The company is based in Livingston, UK. The company has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and chikungunya. Valneva's portfolio also includes two commercial vaccines for travelers. | Biotechnology | Director/Board Member Director/Board Member | |
| Technische Hochschule Mittelhessen | College/University | Graduate Degree | |
| MVM Gp (No.3) Scottish LP | Director/Board Member | ||
Devialet SA
 Devialet SA Electronics/AppliancesConsumer Durables Devialet SA manufactures audio integrated amplifiers. Its products include Devialet 120, Devialet 400, Devialet 200, and Devialet 800. The firm also offers home audio amplification system called Devialet ensemble, D-Premier, and Devialet 250. The company was founded by Pierre-Emmanuel Calmel, Mathias Moronvalle, Emmanuel Nardin, and Quentin Sannié in 2007 and is headquartered in Paris, France. | Electronics/Appliances | Director/Board Member | |
| PIXIUM VISION | Medical Specialties | Director/Board Member | |
| GENSIGHT BIOLOGICS S.A. | Pharmaceuticals: Major | Director/Board Member | |
| Bpifrance Participations SA | Financial Conglomerates | Chief Investment Officer | |
| Grimaud Deyang Animal Co. Ltd. | Chairman Director/Board Member | ||
| Chengdu Grimaud Breeding Co. Ltd. | Chairman Director/Board Member | ||
Valneva Austria GmbH
 Valneva Austria GmbH Miscellaneous Commercial ServicesCommercial Services Part of Valneva SE, VALNEVA Austria GmbH is an Austrian biotechnology company that develops and commercializes vaccines for infectious diseases. The company is based in Vienna, Austria. The CEOs are Thomas Lingelbach, Franck Charles Marie Grimaud, Frédéric Jacotot. The company was founded in 2013. | Miscellaneous Commercial Services | Chief Executive Officer Chief Executive Officer Chief Executive Officer Corporate Officer/Principal | |
Vaccines Holdings Sweden AB
 Vaccines Holdings Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Vaccines Holdings Sweden AB develops and distributes vaccines and biological products. The company is based in Solna, Sweden. Franck Charles Marie Grimaud has been the CEO of the Swedish company since 2014. | Biotechnology | Chief Executive Officer Chairman Director/Board Member | |
Valneva Sweden AB
 Valneva Sweden AB BiotechnologyHealth Technology Part of Valneva SE, Valneva Sweden AB is a specialty vaccine company that focuses on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The company is based in Solna, Sweden and is primarily focused on marketing and distributing Valneva's vaccines Dukoral®, Ixiaro®, and Kamrab™. Valneva has several vaccines in development, including unique vaccines against Lyme disease, COVID-19, and Chikungunya. Additionally, Valneva's portfolio includes two commercial vaccines for travelers. | Biotechnology | Director/Board Member Chairman Director/Board Member Director/Board Member | |
| Intercell Austria AG | Director/Board Member Corporate Officer/Principal Chief Executive Officer | ||
Valneva UK Ltd.
 Valneva UK Ltd. Medical/Nursing ServicesHealth Services Part of Valneva SE, Valneva UK Ltd. provides health care services. The company is based in London, UK and was founded in 2015. | Medical/Nursing Services | Director/Board Member Director/Board Member Director/Board Member | |
Valneva Canada, Inc.
 Valneva Canada, Inc. Medical DistributorsDistribution Services Part of Valneva SE, Valneva Canada, Inc. engages in marketing and distribution of vaccines. The company is based in Kirkland, Canada. | Medical Distributors | President Director/Board Member | |
| Valneva USA, Inc. | Chief Executive Officer Chief Executive Officer | ||
| MVM Scotland (No. 3) GP Ltd. | Director/Board Member | ||
Patient Connect Ltd.
 Patient Connect Ltd. Medical/Nursing ServicesHealth Services Patient Connect Ltd. provides supporting services for patients at the point of dispensing. It operates a community where pharmacists provide medicines to help patients. The firm offers patient compliance services. The company was founded by Grace Lomax and Zoe Barker in 2004 and is headquartered in Guildford, the United Kingdom. | Medical/Nursing Services | Chairman |
Statistieken
Internationaal
| Frankrijk | 20 |
| Verenigd Koninkrijk | 15 |
| Verenigde Staten | 5 |
| Oostenrijk | 4 |
| Duitsland | 3 |
Sectoraal
| Health Technology | 19 |
| Finance | 7 |
| Consumer Services | 5 |
| Process Industries | 3 |
| Commercial Services | 3 |
Operationeel
| Director/Board Member | 106 |
| Corporate Officer/Principal | 44 |
| Chief Executive Officer | 31 |
| Chairman | 29 |
| President | 27 |
Sterkste connecties
| Insiders | |
|---|---|
| Frédéric Grimaud | 33 |
| James Sulat | 23 |
| Franck Grimaud | 22 |
| Anne-Marie Graffin | 22 |
| Sharon Tetlow | 21 |
| Maïlys Ferrère | 21 |
| Thomas Casdagli | 18 |
| Thomas Lingelbach | 17 |
| Peter Buhler | 14 |
| Jim Connolly | 12 |
| Kathrin Jansen | 7 |
| Frédéric Jacotot | 6 |
| Klaus Schwamborn | 4 |
| Wolfgang Bender | 4 |
| Johanna Willemina Pattenier | 4 |
- Beurs
- Insiders
- Juan Carlos Jaramillo
- Bedrijfsconnecties
